CSOP Hang Seng Biotech ETF (03174.HK) Rises 0.55% Intraday as Record 29 Chinese Studies Make ESMO Late-Breaker List

NewTimeSpace News: As of 13:32 on October 21, the CSOP Hang Seng Biotech ETF (03174.HK) rose 0.55% to a latest price of HK$3.642. The ETF has traded 402,900 units so far today for a turnover of HK$1.4887 million at an average price of HK$3.695, with a turnover rate of 0.157%. It is up 0.55% so far this week. Its current net asset value per unit is HK$3.6233, and its assets under management stand at HK$931 million.

(Note on scope: the net asset value per unit and assets under management are as of October 20, 2026; the week-to-date change is measured against the closing price of HK$3.622 on October 20.)

On the news front, the innovative drug sector continued to strengthen on October 21, with the Hang Seng Biotech Index up more than 2% intraday; Hansoh Pharmaceutical rose more than 8%, WuXi Biologics and Kelun-Biotech more than 3%, Zai Lab 5.51%, Duality-B 5.34% and Akeso 4.38%. In terms of catalysts, the 2026 congress of the European Society for Medical Oncology (ESMO) will be held in Madrid, Spain from October 23 to 27, with a total of 29 Chinese innovative drug studies selected as late-breaking abstracts (LBA) — about one third of the congress total and a record high — five of which made the presidential session. Separately, OpenAI announced the acquisition of AI biotech start-up Orchestra Bio, to be integrated with its Rosalind AI model and tools for life-science research, and Akeso's overseas partner Summit Therapeutics reached a strategic collaboration with AstraZeneca, with the latter making a US$2 billion strategic investment to advance studies including ivonescimab combined with ADCs. Akeso is a top-10 constituent of the Hang Seng Biotech Index.

The CSOP Hang Seng Biotech ETF (03174.HK) closely tracks the Hang Seng Biotech Index. The index reflects the overall performance of the 30 largest biotechnology companies listed in Hong Kong that are also eligible for Southbound trading, including pre-revenue companies listed under Chapter 18A of the Listing Rules; its constituents span the Hang Seng Industry Classification System sub-sectors of biotechnology, pharmaceuticals, pharmaceutical distribution, pharmaceutical and biotech contract services, and medical devices and supplies, and are weighted by freefloat market capitalisation with a 10% cap on any single constituent.

Sinolink Securities noted that policy resonance at home and abroad highlights innovation value: the regulatory environment is undergoing a deep reshaping, with policy fully focused on "genuine innovation" and high-quality clinical gains; domestic support policies extend from the front end of review and approval to the full chain of post-listing pricing, hospital adoption and use, and the mild collective procurement expectations for biosimilars are gradually being fulfilled, bringing policy dividends. Overseas, Chinese new drugs are stepping into key clinical nodes with an increasingly clear regulatory system, and leading companies with rigorous multi-regional clinical trial (MRCT) data and differentiated technology platforms are expected to benefit in particular, with global competitiveness further highlighted.